AllerGene AI Therapeutics to Unveil First-in-Class In Vivo mRNA-LNP CAR-T Platform Targeting Mast Cells at Hanson Wade Summit
核心洞察
AllerGene AI Therapeutics (搜索) will present its first-in-class in vivo mRNA-LNP CAR-T approach designed to selectively eliminate disease-driving mast cells at the 5th In Vivo Cell Engineering & Gene Editing Summit in Boston.
The platform engineers CAR-T cells directly in the body using T cell-targeted lipid nanoparticles, offering a potentially safer and more scalable alternative to conventional ex vivo CAR-T manufacturing.
The technology targets mast cell-driven diseases including mastocytosis (搜索), chronic urticaria (搜索), food allergies (搜索), allergic asthma (搜索), and anaphylaxis (搜索), aiming to reset the underlying allergic immune response rather than merely suppress symptoms.
MIAMI, July 21, 2026 — AllerGene AI Therapeutics (搜索), a biotechnology company pioneering next-generation in vivo mRNA-LNP CAR-T therapies for mast cell-driven diseases, announced that Founder and CEO Sidharth "Sid" Kerkar, M.D., will present the company's novel therapeutic platform at Hanson Wade's 5th In Vivo Cell Engineering & Gene Editing Summit, taking place July 28 through 30, 2026, in Boston, Massachusetts.
Dr. Kerkar's presentation, titled "In Vivo mRNA-LNP CAR-T Cells Targeting Mast Cells for Mast Cell-Driven Diseases, Severe Allergies & Anaphylaxis (搜索)," is scheduled for Thursday, July 30, 2026, at 11:00 a.m. The presentation will showcase AllerGene's strategy to engineer CAR-T cells directly in vivo using messenger RNA delivered via T cell-targeted lipid nanoparticles (tLNPs), with the goal of creating a scalable, off-the-shelf therapeutic platform capable of selectively eliminating disease-driving mast cells.
A Paradigm Shift in Treating Mast Cell-Driven Diseases
AllerGene is developing what it believes could represent a new therapeutic category aimed at resetting allergic immune responses. The company's platform employs transient, in vivo-generated CAR-T cells that selectively target tissue-resident mast cells, leveraging the advantages of mRNA-LNP delivery to circumvent the complexities of traditional ex vivo CAR-T manufacturing.
"Current therapies for severe allergies and mast cell-driven diseases largely focus on controlling symptoms or modulating immune responses," said Dr. Kerkar. "Our goal is fundamentally different. We are developing an in vivo CAR-T platform designed to selectively eliminate disease-driving mast cells, with the potential to reset the underlying allergic immune response rather than chronically suppress it."
The company believes this approach could ultimately transform how mast cell-driven diseases — including mastocytosis (搜索), chronic urticaria (搜索), allergic asthma (搜索), food allergies (搜索), and anaphylaxis (搜索) — are treated.
Integrating Cell Therapy, RNA Delivery, and Mast Cell Biology
AllerGene's platform integrates advances across three domains: cell therapy, RNA delivery, and the biology of allergic diseases. By engineering immune cells directly in the body using mRNA-LNP technology, the company is developing novel mRNA CAR constructs that selectively target human mast cells. The approach evaluates transient, controllable, and repeatable in vivo immune cell engineering as a potentially safer and more scalable alternative to conventional ex vivo CAR-T manufacturing.
"Targeting mast cells with precision and durability has long been an important but challenging goal in allergy and immunology," said Bruce S. Bochner, M.D., Professor Emeritus, Division of Allergy & Immunology, Northwestern University Feinberg School of Medicine, and an advisor to AllerGene AI Therapeutics (搜索). "AllerGene's in vivo CAR-T strategy is a scientifically compelling approach that could open new possibilities for patients with mast cell-driven diseases and severe allergic disorders, where current therapies often fall short of addressing the underlying cellular drivers of disease."
Roadmap Toward Clinical Development
At the Hanson Wade summit, Dr. Kerkar will discuss the significant unmet medical need for mast cell-driven diseases and highlight the company's development path and roadmap toward first-in-human studies. AllerGene's research and development efforts are supported by its proprietary CurieCell AI Engine, an integrated research intelligence interface that provides access to leading artificial intelligence models and public biomedical knowledge sources while incorporating the company's proprietary internal R&D data.
The company's platform represents a convergence of mRNA delivery technology — similar in principle to that validated by COVID-19 vaccines — with CAR-T cell engineering, applied to an entirely new therapeutic area beyond oncology. By generating CAR-T cells directly in the patient, AllerGene aims to eliminate the need for lymphodepletion, ex vivo cell manipulation, and the logistical burdens associated with traditional CAR-T therapy.